Follow us

Pipeline

Proof of concept to be generated by 8 clinical trials

Indications

Protocol

Location

Preclinical

Clinical Stage

Phase 1

Phase 2

Phase 3

Brain Metastases

NANORAD 2
CHU Grenoble-Alpes

100 patients randomized

Recruiting Phase 2

NANOBRAINMETS
Harvard Medical School,
Dana Farber Cancer Institute
134 patients randomized

Recruiting Phase 2

Cervical Cancer

NANOCOL
Institut Gustave Roussy
12 patients

Recruiting Phase 1

Pancreatic/
Lung Cancer

NANOSMART
Harvard Medical School
Dana Farber Cancer Institute
100 patients randomized

Recruiting Phase 1

Glioblastoma

NANO-GBM
Centre Jean Perrin
66 patients randomized

Phase 1/2 protocol approved

Other Indications

(Rectal, Head & Neck, Musculoskeletal tumor)

NANOREC
Leeds University
34 patients

Phase 1/2 protocol in preparation

NANOPRO
Centre François Baclesse

46 patients

Phase 2 protocol approved

NANORT-MSK
Centre Léon Bérard
132 patients randomized

Phase 2 protocol approved

ODD: Orphan Drug Designation obtained from the FDA